ABSTRACT
In recent years, the characteristics of the stages of pre-type 1 diabetes have been studied in different cohorts of individuals at risk, leading to the identification of disease-associated biomarkers that can now be applied to risk assessment and disease prediction. These studies have also demonstrated that progression to disease is not uniform and that, in order to optimize risk assessment, demographic, genetic, immune, and metabolic predictive markers should be combined. This chapter will summarize current knowledge on type 1 diabetes-associated risk markers and their potential use for screening purposes, and will suggest how prediction strategies could be translated into clinical application, if and when an effective form of intervention to prevent type 1 diabetes is identified.
